Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $1.1 million.

  • Applied Therapeutics' Share-based Compensation fell 4543.28% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 7449.29%. This contributed to the annual value of $15.6 million for FY2024, which is 11150.82% up from last year.
  • Latest data reveals that Applied Therapeutics reported Share-based Compensation of $1.1 million as of Q3 2025, which was down 4543.28% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Applied Therapeutics' Share-based Compensation peaked at $9.2 million during Q4 2024, and registered a low of $1.1 million during Q3 2025.
  • Its 3-year average for Share-based Compensation is $2.5 million, with a median of $1.9 million in 2024.
  • As far as peak fluctuations go, Applied Therapeutics' Share-based Compensation soared by 46623.62% in 2024, and later tumbled by 4543.28% in 2025.
  • Quarter analysis of 3 years shows Applied Therapeutics' Share-based Compensation stood at $1.6 million in 2023, then surged by 466.24% to $9.2 million in 2024, then plummeted by 87.61% to $1.1 million in 2025.
  • Its Share-based Compensation stands at $1.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $1.5 million for Q1 2025.